Di seguito l'elenco completo dei nostri comunicati stampa (pagina 18 di 28):
GRI Bio receives a new US patent covering novel compound compositions that strengthen its immunomodulatory platform and IP estate.
Eyestem receives CDSCO approval to begin Phase 2 trials of Eyecyte-RPE for geographic atrophy in dry age-related macular degeneration.
Kiora Pharmaceuticals appoints renowned retina specialist Dr. Taiji Sakamoto to advise its retinal disease programs.
Spore.Bio appoints microbiology expert Dr. Michael J. Miller as VP to strengthen regulatory strategy and rapid method validation.
Cardiff Oncology appoints Mani Mohindru as interim CEO to advance onvansertib into late-stage development.
Roche reports positive Phase II data for CT-388, showing up to 22.5% placebo-adjusted weight loss in obesity patients.
Belite Bio completes enrollment in its Phase 2/3 DRAGON II trial evaluating tinlarebant for adolescents with Stargardt disease.
FDA lifts the clinical hold on Intellia’s Phase 3 MAGNITUDE-2 trial of nexiguran ziclumeran for ATTRv-PN patients.
Science 37 names Kelly Johnston McKee as VP of Strategy & Transformation to drive patient-centric innovation and trial modernization.
Quoin submits a Japan Orphan Drug Designation application for QRX003, targeting Netherton Syndrome with Fast Track eligibility.
Propanc Biopharma files a new provisional patent covering novel proenzyme formulations to advance its PRP cancer therapy platform.
Lexeo appoints senior cardiovascular leaders and advances its RNA partnership to accelerate late-stage genetic heart disease programs.
Halo Pharma becomes an independent CDMO following Noramco’s API business sale, sharpening focus on drug product and sterile manufacturing.
CytoDyn receives benefactor funding to support an Expanded Access Program for leronlimab in triple-negative breast cancer patients.
Cloudbreak reports a successful FDA End-of-Phase 2 meeting, paving the way for Phase 3 development of CBT-004 for pinguecula.
Ardelyx doses the first patient in its Phase 3 ACCEL trial evaluating IBSRELA for chronic idiopathic constipation.
BioNTech names Kylie Jimenez as Chief People Officer to support its evolution into a multi-product oncology company by 2030.
Elevar Therapeutics submits an FDA NDA for lirafugratinib as a second-line treatment for FGFR2-driven cholangiocarcinoma.
FDA clears Life Biosciences’ IND for ER-100, enabling first human trials of an epigenetic rejuvenation therapy for vision loss.
Pacira BioSciences adds former BMS CMO Samit Hirawat, MD, to its Board to strengthen leadership in non-opioid pain therapies.
Seamless Therapeutics enters a global research and licensing deal with Eli Lilly to develop recombinase-based gene therapies for hearing loss.
FDA clears Siren Biotechnology’s first IND, enabling a first-in-human AAV-based gene therapy trial for recurrent glioma.
Chugai submits a Japan regulatory filing to expand Tecentriq as adjuvant therapy for MRD-positive muscle-invasive bladder cancer.
FDA grants Breakthrough Therapy Designation to Biogen’s litifilimab for cutaneous lupus erythematosus, supporting accelerated development.
FDA grants Breakthrough Therapy Designation to Immix Biopharma’s NXC-201 for relapsed or refractory AL amyloidosis.
Intelligent Bio Solutions launches a clinical study to support FDA 510(k) clearance of its fingerprint-based codeine test system.
Novartis debuts a national awareness campaign highlighting PSA blood tests as the first step in prostate cancer screening.
Elevar appoints DG Kim as CEO to lead commercialization after NDAs for rivoceranib-camrelizumab and lirafugratinib in liver and bile duct cancers.
Palisade Bio appoints Drs. Peyrin-Biroulet and Rubin to guide PALI-2108 development, strengthening expertise in next-generation IBD therapies.
NurExone names Eyal Gabbai to its board, replacing Dr Gadi Riesenfeld, who will remain with the company on its Scientific Advisory Board.
FDA requests more pediatric data and batch testing info for Joenja® sNDA in children 4–11 with rare APDS; adult approval remains unaffected.
Quotient names Susan Keefe as CFO, adding 30 years of life science finance and Flagship Pioneering experience to support its growth in somatic genomics.
Sparrow Pharmaceuticals adds biopharma veteran Carlo Incerti to its board as the company prepares pivotal trials of clofutriben for type 2 diabetes
Alvotech signs deals with Sandoz to supply and commercialise several biosimilars across Canada and Australia, New Zealand markets.
Novo Medi Sciences launches G.A.U.R.I., a nationwide missed-call campaign to support immunization of underprivileged girl children across India.
OPKO and Entera expand partnership to develop a once-daily oral LA-PTH tablet for hypoparathyroidism, targeting FDA IND in 2026.
Oncolytics’ pelareorep wins FDA Fast Track in 2L KRAS-mutant MSS mCRC after strong survival and response data.
Levicept appoints James Sandy as CDO to lead LEVI-04, a first-in-class osteoarthritis therapy after promising Phase II trial results.
Dewpoint doses first patient in Phase 1a/2a trial of DPTX3186, a first-in-class beta-catenin modulator for advanced solid tumors.
Aprea appoints Dr. Eugene Kennedy as Chief Medical Advisor to advance WEE1 inhibitor APR-1051 after early Phase 1 results in solid tumors.
Bristol Myers Squibb partners with Kasey Keller to share his NHL journey and raise awareness of Breyanzi CAR T therapy.
Bristol Myers Squibb and Johnson & Johnson launch an educational initiative on factor XIa‑targeted strategies to reduce clot risk without increasing bleeding in thromboembolic disease.
Biogen’s DEVOTE study shows higher-dose nusinersen improved motor outcomes in SMA with a safety profile similar to SPINRAZA.
MetaVia and Syntekabio use AI modeling to identify new inflammation, cardiometabolic and cancer targets for vanoglipel beyond MASH and T2D.
Rigel names former Jazz executive Michael Miller to its board, adding four decades of biotech and pharma leadership experience.
LeonaBio names Mark Kubik as CBO to strengthen partnerships, licensing, and strategic growth as the company advances its oncology pipeline.
Adial applauds U.S. legislation directing FDA and NIDA to adopt broader clinical endpoints for addiction and AUD therapies.
Tempest closes an all-stock CAR-T acquisition and financing deal, adding oncology assets and extending its cash runway.
Sun Pharma enters cricket sponsorship as RCB’s Principal Sponsor and Health Partner in a three-year T20 deal to boost brand reach.
Pfizer adds over 30 medicines to TrumpRx with discounts up to 85% and partners with GoodRx to expand prescription affordability.
Cognizant forms a strategic alliance with Palantir to modernise TriZetto and expand governed AI across healthcare and enterprises.
Novo Nordisk criticizes Hims & Hers for mass compounding a semaglutide pill, citing FDA concerns, safety risks, and legal violations.
Alvotech posts positive pharmacokinetic results for AVT80, supporting clinical similarity for SC and IV vedolizumab biosimilars.
Sun Pharma introduces SUNday, a year-round skin cancer awareness initiative focused on education, patient support, and community engagement.
ADARx appoints Dr. Donald Fong as CMO to oversee Phase 3 and Phase 2 trials and drive late-stage RNA therapeutic development.
Polaryx appoints Dr. Mitchel Berger, Francis Braun, and Dr. Charles Ryan to its Board as PLX-200 enters Phase 2 development.
RenovoRx names Mark Voll CFO effective Feb 2026 to drive commercial growth, RenovoCath rollout, and Phase III TIGeR-PaC execution.
New Indian report calls for rapid adoption of non-animal testing to boost drug innovation, reduce R&D costs, and support India’s $500B pharma goal.
Novartis begins construction of a major San Diego research center to advance AI-powered drug discovery as part of its $23B US expansion.
Pfizer secures FDA Priority Review to expand HYMPAVZI use in children and inhibitor hemophilia patients, with a Q2 2026 decision.
Pharma Now podcast features Dr. ARM Rao on pharma quality leadership, compliance strategy, digital QMS, and global regulatory excellence.
Oryzon doses first patient in a Yale-led Phase Ib trial testing iadademstat with radiation and atezolizumab in recurrent ES-SCLC.
China fast-tracks Eisai and Biogen’s subcutaneous LEQEMBI, paving the way for weekly at-home dosing for Alzheimer’s disease patients.
Roche reports Phase III data showing fenebrutinib matched OCREVUS in PPMS, reduced disability risk and supports regulatory filing plans.
Anuh Pharma’s Tarapur manufacturing site clears USFDA inspection with no observations, underscoring global GMP compliance.
Chugai presented Phase I/II data showing NXT007 was well tolerated when hemophilia A patients switched from emicizumab without washout.
Oragenics plans Phase 2 trials of intranasal ONP-002 for concussion and mTBI, targeting rapid brain delivery and early intervention.
Ocugen names Rita Johnson-Greene as CFO, adding 20+ years of gene therapy, finance, and commercial leadership ahead of BLA filings.
Milestone names David Sandoval General Counsel and Chief Compliance Officer as it launches FDA-approved CARDAMYST for PSVT.
Celularity secures USD 12.2M in non-dilutive funding through the sale of New Jersey NOLs and R&D tax credits under the NJEDA program.
Medicus Pharma receives FDA clearance to begin a Phase 2b dose-optimization study of Teverelix in advanced prostate cancer patients.
Chugai licenses Araris’ AraLinQ ADC platform to develop a new oncology program, with upfront payment and milestones worth up to $780M.
FDA accepts Takeda’s oveporexton NDA for narcolepsy type 1 with Priority Review, setting a Q3 decision for a first-in-class orexin therapy.
Enanta will present preclinical data on its KIT inhibitor EDP-978 at AAAAI 2026, highlighting mast-cell targeting and once-daily dosing potential.
Biologics X 3DCC 2026 unites 850+ delegates in Goa, advancing biologics innovation and 3D cell culture technologies.
Madrigal secures global rights to six preclinical siRNA programs for MASH from Ribo in a deal worth up to $4.4B
FDA approves KEYTRUDA plus chemotherapy for PD-L1+ platinum-resistant ovarian cancer based on Phase 3 KEYNOTE-B96 results.
Tempest reports post-transaction plan to advance TPST-2003, expand into in vivo CAR-T, and progress oncology programs with partner funding.
Thermo Fisher and Datavant collaborate to securely link real-world data with clinical trials, strengthening RWE generation for biopharma.
Biogen appoints Dr. Maria C. Freire as Chair of the Board, succeeding Caroline Dorsa following the 2026 Annual Meeting.
Vaxcyte begins OPUS-3 Phase 3 study of VAX-31 in adults previously vaccinated against pneumococcus, supporting a planned FDA BLA.
Mesoblast presents data supporting early Ryoncil® use in SR-aGvHD and plans a pivotal adult trial to expand beyond pediatrics.
Nxera partners with investor-backed NewCo to advance a GPCR asset globally, securing equity, milestones, royalties, and retaining APAC rights.
Oryzon names Rolando Gutierrez-Esteinou as Chief Medical Officer to lead CNS programs and advance vafidemstat into late-stage trials.
BridgeBio reports positive Phase 3 PROPEL 3 results for oral infigratinib in achondroplasia, showing significant height gains and favorable safety.
Cue Biopharma appoints Lucinda Warren as Chief Financial and Business Officer, adding senior finance and deal-making expertise to leadership.
Oncotelic and Sapu strengthen global IP protection for OT-101, expanding CNS, oncology, and intracranial drug delivery coverage.
Roche’s Phase III MAJESTY study shows Gazyva significantly improves complete remission rates in primary membranous nephropathy vs tacrolimus.
SEOPRO showcases AI-driven pharma portfolio governance at Pharma Project Portfolio Management Summit 2026.
Kane Biotech resumes U.S. and Canada sales of revyve® wound gel and appoints new VPs to rebuild North American commercial operations.
NovaBridge doses first patient in Phase 2 trial of givastomig with nivolumab and mFOLFOX6 for HER2-negative metastatic gastric cancer.
Palisade Bio appoints Bram Verstockt, MD, PhD, to guide Phase 2 development of PALI-2108 in ulcerative colitis and Crohn’s disease.
Sana names Brian Piper CFO as it prepares clinical readouts for SC451 in type 1 diabetes and SG293 in B-cell disease.
Telix submits EU marketing application for TLX101-Px brain cancer imaging agent, aligning with upcoming U.S. FDA filing.
Biofrontera locks Phase 1 PK study for Ameluz PDT, supporting a 2026 sNDA to expand actinic keratosis treatment to 240 cm² areas.
EU clears Novo Nordisk’s 7.2 mg Wegovy dose, allowing three 2.4 mg weekly injections for patients needing additional weight loss.
Kane Biotech secures FDA 510(k) clearance for revyve wound cleanser and expands ISO 13485 MDSAP certification under new QMSR.
Oculis appoints Katie Kazem as Chief Legal Officer to lead legal, compliance, and governance as key late-stage programs advance.
Fortrea names Scott Dove President of Clinical Pharmacology Services as Oren Cohen focuses exclusively on Chief Medical Officer duties.
Essential Pharma acquires Ventavis from Bayer and global Breelib rights, strengthening its rare cardio-pulmonary disease portfolio.
Pfizer announces positive PFS results from BREAKWATER Cohort 3 for BRAFTOVI combo in BRAF V600E metastatic colorectal cancer.
FDA accepts BMS NDA for iberdomide combo in relapsed or refractory multiple myeloma and grants Breakthrough Therapy status.
Cue Biopharma shares positive preclinical safety data for CUE-401, showing strong tolerability in mouse and primate studies.
PHARMAP 2026 in Amsterdam explores patient-friendly pharma design with leaders from Bayer AG, HSLU and Sidewise.
Pluri gains China patent for its 3D immune cell expansion technology, expanding global IP protection across key cell therapy markets.
Tarsus names eye-care veteran David Pyott to its Board to support XDEMVY commercialization and advance its ophthalmology pipeline.
Tenvie Therapeutics appoints Don O’Sullivan as CBO to drive corporate and business development as its pipeline nears key clinical milestones.
Zealand Pharma posts positive Phase 1a SAD results for Kv1.3 blocker ZP9830, demonstrating safety, tolerability, and dose-proportional PK.
LIXTE appoints Sidney Braun as CEO of Liora Technologies Europe to drive LiGHT proton therapy expansion and long-term growth.
Crescent Biopharma initiates ASCEND Phase 1/2 trial, dosing first patient with CR-001 for advanced solid tumors.
Aspargo Labs appoints Sam Backenroth as CFO to lead financial strategy and support U.S. and European product launches.
ImmunityBio’s ANKTIVA plus BCG becomes the first authorized treatment in Europe for BCG-unresponsive non-muscle invasive bladder cancer.
Silo Pharma receives Japanese patent allowance for SPC-15, expanding global IP protection for its PTSD treatment candidate.
Novartis posts positive Phase III RemIND results for remibrutinib in chronic inducible urticaria and submits sNDA to FDA.
Charles River appoints Glenn Coleman as CFO and Kerry Dailey as Chief Legal Officer to strengthen leadership and drive long-term growth.
Theriva out-licenses SYN-020 to Rasayana in a deal worth up to $38M plus royalties, granting global development and commercial rights.
Syntegon unveils AIM9, a 600 vials/min inspection platform with integrated CCIT and AI-powered visual defect detection.
Sandoz signs new European vPPAs under the Energise program to reduce Scope 2 emissions and boost renewable energy across its supply chain.
Merck teams up with Mayo Clinic to harness AI, genomic and multimodal data to accelerate early-stage drug discovery and development.
Candel Therapeutics lands $100M royalty financing from RTW to fund aglatimagene launch in early prostate cancer, pending FDA approval.
Starton Therapeutics doses first patient in Phase 2a STAR-LLD study for relapsed/refractory multiple myeloma, expanding to six U.S. sites.
Serina Therapeutics enrolls first patient in Phase 1b registrational trial of SER-252 for advanced Parkinson’s disease.
Kane Biotech broadens U.S. reach of its revyve® wound care line through new distribution deals with Patient Care Medical and Life Biologics.
Merck shares positive second RSV season data for ENFLONSIA in high-risk children, with Phase 3 SMART trial supporting broader use.
Chugai launches ELEVIDYS gene therapy for Duchenne muscular dystrophy in Japan following conditional approval and NHI listing.
NovaBridge names Emmett Cunningham Jr. Vice Chairman and R&D Committee member, strengthening biotech leadership and innovation strategy.
Artiva Biotherapeutics names Elaine Sorg to Board to guide AlloNK development for rheumatoid arthritis and autoimmune diseases.
Zenyaku and Chugai secure Japan MHLW approval to expand Rituxan use to autoimmune hemolytic anaemia under public knowledge-based application.
AtaiBeckley names Michael Faerm CFO as BPL-003 advances toward Phase 3; Anne Johnson transitions to Chief Accounting Officer.
ImmunityBio partners with Accord Healthcare to commercialise ANKTIVA in Europe and launches Irish subsidiary to strengthen EU operations.
Outlook Therapeutics signs exclusive deal with Mediconsult AG to distribute LYTENAVA™ (bevacizumab gamma) in Switzerland for retina diseases.
AstraZeneca’s Calquence plus venetoclax approved in the US based on Phase III AMPLIFY results as first fixed-duration oral CLL/SLL regimen.
AstraZeneca’s Calquence plus venetoclax wins FDA approval as the first fixed-duration, all-oral regimen for first-line CLL and SLL treatment.
FDA accepts Roche’s NDA for giredestrant plus everolimus in ER-positive, ESR1-mutated advanced breast cancer; decision due December 2026.
MoonLake shares positive Phase 2 sonelokimab results in axSpA and reports 2025 financial results with $394M cash position.
Takeda reports positive Phase 3 KEPLER results, with ENTYVIO achieving remission and showing safety in pediatric ulcerative colitis.
Dr. François Nader appointed Chair and independent director at Tectonic Therapeutics, bringing 30+ years of biotech leadership experience.
Palisade Bio presents clinical, histologic and RNA-seq data showing targeted activity of PALI-2108 at ECCO 2026.
Former Pfizer CSO Dr. Mikael Dolsten joins Neutrolis as Executive Director to advance fast-acting, NET-targeting therapies.
AIM ImmunoTech shares Phase 2 DURIPANC study progress evaluating Ampligen® with Imfinzi® in metastatic pancreatic cancer after FOLFIRINOX.
Akari Therapeutics appoints RNA biology and cancer research leader Dr. Olga Anczukow to its Scientific Advisory Board.
Fortress Biotech and Cyprium Therapeutics sell rare pediatric priority review voucher for $205M following FDA approval of ZYCUBO.
Kyntra Bio to present Phase 1b/2 data on FG-3246 plus enzalutamide in mCRPC at ASCO GU 2026, showing encouraging rPFS results.
AbbVie will invest $380M to build two AI-integrated API facilities in North Chicago, expanding U.S. manufacturing and creating 300 jobs.
Adial points to new FDA evidentiary flexibility as it advances AD04 for Alcohol Use Disorder and plans regulatory alignment
Foghorn names Ryan Maynard CFO, adding 25+ years of biotech finance and capital markets experience to support pipeline growth.
BMS announces positive Phase 2 results for Reblozyl in alpha-thalassemia, meeting primary endpoints in NTD and TD patients.
Merck splits Human Health into Oncology and Specialty units, naming new leaders to support launches and long-term growth.
European Commission approves Sandoz’s Ranluspec ranibizumab biosimilar for retinal diseases, with EU launch planned in 2H 2026.
IDEAYA names Dr Theodora Ross Chief Development Officer to lead early oncology development and shape long-term R&D strategy.
Novo Nordisk reports 23% weight loss with CagriSema in REDEFINE 4 but misses non-inferiority to tirzepatide at 84 weeks.
Serina doses first patient in Phase 1b registrational SER-252 trial for advanced Parkinson’s, targeting 505(b)(2) pathway.
Transpire Bio Inc. names R. LaDuane Clifton CFO to support its transition from clinical to commercial-stage operations.
Siren Biotechnology secures FDA Fast Track and IND clearance for SRN-101 in recurrent high-grade glioma.
Sanofi and Regeneron secure U.S. Food and Drug Administration approval for Dupixent in allergic fungal rhinosinusitis.
Novo Nordisk will reduce U.S. list prices of Wegovy, Ozempic and Rybelsus to $675 starting January 2027.
Ardelyx and Ladies Professional Golf Association partner to boost IBS-C education through digital outreach and LPGA Tour activations.
Cosmos Health Inc. appoints Dimitrios Iliopoulos to advance AI-powered drug discovery and clinical development initiatives.
Kyverna Therapeutics appoints Sravan Emany and Andrew Miller to its Board, supporting growth of its autoimmune CAR T pipeline.
EMA authorizes Oryzon’s Phase II IDEAL study of iadademstat in essential thrombocythemia patients resistant to hydroxyurea.
TUL and Novo Nordisk report 19.7% weight loss in a Chinese Phase 2 trial of UBT251 triple agonist for obesity.
Pfizer secures full FDA approval for BRAFTOVI plus cetuximab and chemotherapy in BRAF V600E-mutant metastatic colorectal cancer.
Werewolf Therapeutics appoints Piper Sandler to explore strategic alternatives to advance its PREDATOR platform and oncology pipeline.
Aktis Oncology secures FDA Fast Track designation for AKY-1189, a Nectin-4-targeted radiopharmaceutical for metastatic urothelial cancer.
Paratek reports positive Animal Rule data for NUZYRA in pulmonary anthrax, securing additional BARDA procurement support.
INTERPHEX WEEK TOKYO 2026 at Makuhari Messe features 950 exhibitors, 35K professionals, 320+ seminars on pharma manufacturing, DX, and regenerative medicine expo.
Zydus Lifesciences Limited plans India semaglutide launch after patent expiry with reusable adjustable pen under SEMAGLYN, MASHEMA and ALTERME.
Tempest Therapeutics, Inc. reports 100% response rate for TPST-2003 CD19/BCMA CAR-T in REDEEM-1 Phase 1/2a study.
Rivus Pharmaceuticals Inc. appoints Jorge Bartolome CEO as it advances HU6 and obesity pipeline programs.
Novo Nordisk partners with Vivtex Corporation in a $2.1B agreement to develop oral biologics for obesity and diabetes.
Merck & Co. announces positive Phase 3 results for doravirine/islatravir (DOR/ISL), showing non-inferior efficacy in HIV-1.
Intelligent Bio Solutions deploys first Syrma Johari-manufactured fingerprint drug readers, targeting 40% cost savings and U.S. market expansion.
GSK’s ViiV Healthcare reports Phase 1 VH184 data showing 6-month drug levels; VH499 capsid inhibitor supports twice-yearly HIV dosing.
ViiV’s EMBRACE Phase IIb shows 94% viral suppression at 12 months with IV lotivibart plus CAB LA, supporting twice-yearly HIV dosing.
GSK to acquire 35Pharma for $950M, adding Phase I HS235 targeting activin signalling in pulmonary hypertension and PH-HFpEF.
AMA approves Category III CPT code X566T to track CED delivery of Plus Therapeutics’ REYOBIQ in rGBM and pediatric brain cancer.
FDA approves Merck Animal Health’s NUMELVI (atinvicitinib), first second-gen JAK inhibitor for pruritus in canine allergic dermatitis.
Hikma launches authorised generic Nucynta (tapentadol) IR in the US; brand posted $157M sales in 2025, expanding opioid pain portfolio.
Novartis to build 46,000 sq ft RLT facility in Denton, Texas, its fifth US site, under a $23B investment to scale radioligand therapy supply.
IDEAYA enrolls first patient in Phase 1 IDE034 (PTK7/B7H3 TOP1 ADC), triggering $5M Biocytogen milestone; combo cohorts with IDE161 planned.
India Pharma Expo 2026 at HITEX Hyderabad features 300+ exhibitors, NextGen Awards, buyer-seller meets on Pharma 4.0, biosimilars, AI, and global partnerships.
Rhythm’s Phase 3 TRANSCEND shows 16.4% BMI reduction with setmelanotide in acquired HO; FDA PDUFA set for March 20, 2026.
Roche’s Phase III FENhance 1 shows fenebrutinib reduces ARR 51% vs teriflunomide in RMS; safety and mortality data under review.
Septerna’s Phase 1 data show SEP-631, an oral MRGPRX2 NAM, achieved strong mast-cell inhibition; Phase 2b in chronic spontaneous urticaria planned.
Japan’s MHLW grants orphan designation to rilzabrutinib for IgG4-RD after positive Phase 2 data; Phase 3 RILIEF trial ongoing.
FDA accepts Opus Genetics’ sNDA for phentolamine ophthalmic solution 0.75% in presbyopia; PDUFA set for Oct 17, 2026.
Longeveron’s Phase 2b data in Cell Stem Cell show laromestrocel (LOMECEL-B) improved 6MWT by 63m at 9 months in frailty patients vs placebo.
Eminence Business Media's 6th Pharma GMP & Quality Management 2026 in Mumbai covers audit readiness, AI-driven quality, deviation management, and post-event implementation clinic.
Pharma Quality Excellence Awards 2026 celebrate GMP maturity, leadership, and resilient quality systems driving sustainable excellence in pharmaceutical organizations.
Seres Therapeutics appoints Richard Kender Interim CEO as SER-155 nears Phase 2 and Q2 2026 irEC data from MSKCC study.
Hepion licenses ctRNA liquid biopsy from Cirna Diagnostics to detect early hepatocellular carcinoma, expanding its HCC precision diagnostics pipeline.
Adial enters exclusivity with Molteni to commercialize AD04 in Europe; deal worth up to $60M in milestones and royalties ahead of Phase 3.
EMA’s CHMP adopts negative opinion on Acadia’s trofinetide for Rett syndrome despite positive LAVENDER trial; re-examination planned.
Acadia Pharmaceuticals appoints Vertex SVP Finance Jonathan Poole to its Board and Audit Committee to bolster financial oversight and growth strategy.
GSK completes $2.2B RAPT Therapeutics acquisition, gaining Phase IIb anti-IgE mAb ozureprubart for food allergy; Phase III planned.
Teva inks $400M funding deal with Blackstone Life Sciences to advance Phase 3 TL1A antibody duvakitug in UC and Crohn’s, with milestones and royalties.
Moderna reaches $950M global settlement with Arbutus and Genevant over Spikevax and RSV IP; potential $1.3B contingent under Section 1498 appeal.
AIM ImmunoTech reports ~$1.8M in preliminary subscriptions after its rights offering expired, funding development of Ampligen for pancreatic cancer.
Alterity appoints neurologist Daniel Claassen as Chief Medical Advisor as ATH434 moves toward Phase 3 development for multiple system atrophy.
CervoMed completes Phase 1 PK study of stable neflamapimod crystal form and selects 50 mg TID dosing for upcoming Phase 3 dementia with Lewy bodies tria